Next Article in Journal
Hyperplanar Morphological Clustering of a Hippocampus by Using Volumetric Computerized Tomography in Early Alzheimer’s Disease
Previous Article in Journal
Please Wait, Processing: A Selective Literature Review of the Neurological Understanding of Emotional Processing in ASD and Its Potential Contribution to Neuroeducation
Previous Article in Special Issue
Digital Platforms in the Assessment and Monitoring of Patients with Bipolar Disorder
Article Menu

Export Article

Open AccessReview
Brain Sci. 2017, 7(11), 154; doi:10.3390/brainsci7110154

Systematic Review of Epigenetic Effects of Pharmacological Agents for Bipolar Disorders

Department of Psychiatry & Behavioral Neurobiology, University of Alabama at Birmingham, 1720 7th Avenue South, Birmingham, AL 35233, USA
Department of Psychiatry & Health Behavior, Medical College of Georgia at Augusta University, 997 St. Sebastian Way, Augusta, GA 30912, USA
Author to whom correspondence should be addressed.
Received: 15 October 2017 / Revised: 6 November 2017 / Accepted: 16 November 2017 / Published: 18 November 2017
(This article belongs to the Special Issue Neurological Research of Bipolar Disorder)
View Full-Text   |   Download PDF [322 KB, uploaded 18 November 2017]   |  


Epigenetic effects of medications are an evolving field of medicine, and can change the landscape of drug development. The aim of this paper is to systematically review the literature of the relationship between common medications used for treatment of bipolar disorders and epigenetic modifications. MedLine/PubMed searches were performed based on pre-specified inclusion criteria from inception to November 2017. Six animal and human studies met the inclusion criteria. These studies examined the epigenetic changes in the main classes of medications that are used in bipolar disorders, namely mood stabilizers and antipsychotics. Although these initial studies have small to moderate sample size, they generally suggest an evolving and accumulating evidence of epigenetic changes that are associated with several of the medications that are used in bipolar I and II disorders. In this manuscript, we describe the specific epigenetic changes that are associated with the medications studied. Of the studies reviewed, five of the six studies revealed epigenetic changes associated with the use of mood stabilizers or antipsychotic medications. This review contributes to future research directions. Further understanding of the complexities of the epigenome and the untangling of the effects and contributions of disease states versus medications is crucial for the future of drug design and the development of new therapeutics. Epigenetic therapeutics hold great promise for complex disease treatment and personalized interventions, including psychiatric diseases. View Full-Text
Keywords: epigenetics; epigenomics; antipsychotics; mood stabilizers; bipolar disorders; mood disorders; drug development epigenetics; epigenomics; antipsychotics; mood stabilizers; bipolar disorders; mood disorders; drug development

Figure 1

This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. (CC BY 4.0).

Scifeed alert for new publications

Never miss any articles matching your research from any publisher
  • Get alerts for new papers matching your research
  • Find out the new papers from selected authors
  • Updated daily for 49'000+ journals and 6000+ publishers
  • Define your Scifeed now

SciFeed Share & Cite This Article

MDPI and ACS Style

Lockwood, L.E.; Youssef, N.A. Systematic Review of Epigenetic Effects of Pharmacological Agents for Bipolar Disorders. Brain Sci. 2017, 7, 154.

Show more citation formats Show less citations formats

Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Related Articles

Article Metrics

Article Access Statistics



[Return to top]
Brain Sci. EISSN 2076-3425 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top